Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 16Sarcoma 6Thoracic 3Other hematologic neoplasm 3Lymphoid 3Dermatologic 3Genitourinary 2Plasma cell 1Other solid neoplasm 1Other neoplasm 1Myeloid 1Breast 1

Conditions

Prostatic Neoplasms 2

Interventions

Docetaxel 409pembrolizumab 331Prednisone 289enzalutamide 283Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 252Abiraterone Acetate 217Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 117Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 106cabozantinib 104atezolizumab 104Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cilengitide × Genitourinary × Clear all
NCT00121238 2016-04-28

Cilengitide in Treating Patients With Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00103337 2013-02-28

Cilengitide in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
106 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡